Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing what appears to be a strategic "something for everyone" plan of attack from the pharmaceutical giant.

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who lose fat also tend to lose muscle. This can be particularly dangerous for older adults because it makes them more likely to fall and can worsen osteoporosis.